Gene editing therapy ready for cardiovascular diseases: opportunities, challenges, and perspectives

Gene editing nucleases (GENs), represented by CRISPR/Cas9, have become major tools in biomedical research and offer potential cures for many human diseases.Gene editing therapy (GETx) studies in animal models targeting genes such as proprotein convertase subtilisin/kexin Console type 9 (PCSK9), apolipoprotein C3 (APOC3), angiopoietin Like 3 (ANGPTL3) and flatware set inducible degrader of the low-density lipoprotein receptor (IDOL) have demonstrated the benefits and advantages of GETx in managing atherosclerosis.Here we present our views on this brand new therapeutic option for cardiovascular diseases (CVD).